WO2001027286A1 - Procédé de production d'ubiquinone-10 - Google Patents
Procédé de production d'ubiquinone-10 Download PDFInfo
- Publication number
- WO2001027286A1 WO2001027286A1 PCT/JP2000/007121 JP0007121W WO0127286A1 WO 2001027286 A1 WO2001027286 A1 WO 2001027286A1 JP 0007121 W JP0007121 W JP 0007121W WO 0127286 A1 WO0127286 A1 WO 0127286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- polypeptide
- microorganism
- ubiquinone
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/66—Preparation of oxygen-containing organic compounds containing the quinoid structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a method for producing ubiquinone-10 useful as an antioxidant substance, a method for producing ubiquinone-10 useful as an antioxidant functional substance, a DNA and a polypeptide useful for the method, a new gene expression in microorganisms and microorganisms useful for the method. , And new breeding of microorganisms. Background art
- Ubiquinone is a general term for 2,3-dimethoxy-5-methyl-6-polyprenyl-1,4-benzoquinone, also known as coenzyme Q.
- Ubiquinone is widely present in the biological world as a component of the electron transport system.
- the polyprenyl side chain length of ubiquinone varies depending on the species of organism, and homologues of ubiquinone-1 to 13 'are found naturally.
- the major homolog is ubiquinone-6-: L0, and many mammals, including humans, biosynthesize ubiquinone-10.
- Ubiquinone 10 is effective in improving symptoms of heart failure and other ischemic heart diseases and has been approved as a pharmaceutical. In addition, it has been reported that it is effective in reducing cardiac side effects of anticancer drugs such as adriamycin, improving periodontal disease, and protecting skeletal muscle against exercise load [Vitamin Encyclopedia, The Vitamin Society of Japan (1996)].
- ubiquinone-10 is produced by a synthetic method or an extraction method from microorganisms such as yeasts and photosynthetic bacteria.
- increasing demand has led to a demand for a more efficient production method.
- One of the effective means for accumulating and producing specific substances using microorganisms is to block intermediate metabolites in the biosynthetic pathway leading to the target substance from flowing to other pathways, resulting in more intermediate There is a way to make metabolites flow to the target substance Can be
- Ubiquinone is structurally classified roughly into a quinone skeleton and a polyprenyl side chain.
- Polyprenyl side chain is a kind of isoprenide compound. It is composed of isopentenyl pyrophosphate (IPP) with 5 carbon atoms as a basic skeleton unit, and is synthesized by condensing a plurality of them.
- IPP isopentenyl pyrophosphate
- prenyltransferase A series of enzymes responsible for this reaction is called prenyltransferase.
- Prenyltransferases are found in many species, for example, in Escherichia coli, phenylnesyltransferases with different synthetic chain lengths [J. Biochem., 108, (6), 995-1000 (1990)], Presence of three enzymes, quinone prenyltransferase [J. Bac, 179, 3058-3060 (1997)] and pendecaprenyl transferase [J. Bac, 181, 483-492 (1999)] Were confirmed, and the gene was identified in each case.
- Geranylgeranyltransferase has been identified in the photosynthetic bacterium Rhodobacter sphaeroides (hereinafter abbreviated as sphaeroides) [J. Bac, 177, 2064-2073 (1995)].
- the starting substrate for prenyltransferase which supplies the ubiquinone side chain, is thought to be phenylnesyl pyrophosphate (FPP), which is the starting substrate for many isoprenoid compound biosynthesis.
- FPP phenylnesyl pyrophosphate
- the method of obtaining a carotenoid biosynthesis mutant is performed by using radiation such as ultraviolet rays, X-rays, and ⁇ -rays, and using chemical substances such as sodium nitrite, nitrosguanidine, and methyl methylsulfonate.
- radiation such as ultraviolet rays, X-rays, and ⁇ -rays
- chemical substances such as sodium nitrite, nitrosguanidine, and methyl methylsulfonate.
- a method has been used in which a strain with a changed color is selected from the strains subjected to the mutation treatment, and a strain deficient in carotenoid biosynthesis ability is selected therefrom.
- a method of specifically mutating a gene encoding the enzyme has also been used.
- Various methods have been known so far, but a particularly convenient and frequently used method is to use a vector containing a gene with an incomplete 5 'end and 3' end and integrate it into the homologous region on the chromosome. Method to destroy the gene and inactivate the desired enzyme activity, or use DNA containing a gene whose function has been lost due to deletion, substitution, or insertion of part or all of the gene. Methods are known in which the gene is disrupted by transferring the insertion onto a chromosome, thereby losing the desired enzyme activity.
- Another effective means for accumulating and producing specific substances using microorganisms is to enhance the expression of enzyme genes in the biosynthetic pathway.
- the starting substrate for the quinone skeleton is p-hydroxybenzoic acid biosynthesized via colismic acid biosynthesized via the shikimate pathway.
- the polyprenyl side chain is formed by the condensation of multiple IPPs biosynthesized by the mevalonate pathway or the recently revealed non-mevalonate pathway [Biochem. J., 295, 517 (1993)].
- p—hid Roxybenzoic acid and polyprenyl diphosphate are converted to 4-hydroxy-13-polyprenylbenzoic acid by the action of p-hydroxybenzoic acid-polyprenyltransferase (EC.2.5. 1.39), which undergoes various modifications. , And become ubiquinone.
- Enzymes and genes on these biosynthetic pathways have been largely identified in Escherichia coli and yeast. Although the entire contents of these genes have not yet been elucidated, there are several examples in which the expression of enzyme genes on the ubiquinone biosynthetic pathway was enhanced to increase the amount of ubiquinone accumulation. For example, Zhu et al. Have shown that the accumulation of ubiquinone increases when various ubiquinone biosynthetic enzyme genes derived from E. coli are ligated downstream of the lac promoter and highly expressed in E. coli (J. Fermentation and
- the rate-limiting point on the biosynthetic pathway is identified, genes on the ubiquinone biosynthetic pathway including genes involved in the rate-limiting point are isolated, and the gene and its surrounding bases are isolated. It is important to determine the sequence. Disclosure of the invention
- An object of the present invention is to improve the symptom of heart disease.
- An industrially useful method for producing ubiquinone-10 useful as an antioxidant substance, DNA and polypeptide useful in the method, and useful in the method A novel microorganism, gene expression in the microorganism, and a method for breeding the microorganism.
- the present inventors have intensively studied an industrially useful method for producing ubiquinone-10. Then, in a microorganism belonging to a photosynthetic bacterium, a gene involved in improving ubiquinone-10 biosynthesis was found, and the present invention was completed.
- the present invention relates to the following (1) to (41).
- a microorganism having at least one property and capable of producing ubiquinone-110 is cultured in a medium, ubiquinone-110 is produced and accumulated in the culture, and the ubiquinone-110 is collected from the culture.
- a method for producing ubiquinone-10 characterized in that:
- the reduced or defective geranylgeranyltransferase activity is attributed to the deletion, substitution, or addition of one or more bases in the DNA sequence encoding geranylgeranyltransferase. And a property obtained by introducing a DNA encoding a polypeptide having reduced or deficient geranylgeranyltransferase activity into a microorganism capable of producing ubiquinone-10, 1), manufacturing method.
- deletion, substitution or addition of a base can be carried out by a site-directed mutagenesis method which is a well-known technique before filing.
- Molecular Cloning A Laboratory Manual, Second Edition [Sambrook, Fritsch, Maniatis Edit, Cold Spring Herba. Laboratory Press (Cold Spring Harbor Laboratory Press), 1989 (hereinafter abbreviated as Molecular Cloning Second Edition)], Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997) (hereafter, Current 'Protocol) Abbreviations for "Iluzu 'In-Molecular'Biology", Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci., USA, 79, 6409 (1982), Gene, 34, 315 ( 1985), Nucleic Acids Research, 13, 4431 (1985), Proc. Natl. Acad. Sci USA, 82, 488 (1985), and the like.
- Enhancement of decaprenyl diphosphate synthase activity is achieved by introducing a DNA encoding decaprenyl diphosphate synthase into a microorganism capable of producing ubiquinone-110.
- amino acid deletion, substitution, or addition can be performed by site-directed mutagenesis, which is a well-known technique before filing the application, as in the above-described base deletion, substitution, or addition.
- the number of amino acids to be deleted, substituted or added is not particularly limited, it is preferably one to several tens, particularly preferably one to several amino acids.
- the amino acid sequence having at least 60%, usually 80% or more, particularly 95% or more homology with the amino acid sequence of the enzyme is required. Is preferred.
- homology is calculated using a homology analysis program such as BLAST [J. Mol. Biol., 215, 403 (1990)] or FAST A CMethods EnzymoL, 183, 63 (1990)]. Can be.
- a DNA that hybridizes under stringent conditions is defined as a colony 'hybridization method, a plaque hybridization method, using the DNA of the present invention or a fragment of the DNA as a probe.
- it refers to DNA obtained by using the Southern plot hybridization method or the like.
- DNA from colonies or plaques or a filter on which a fragment of the DNA is immobilized After performing hybridization at 65 ° C in the presence of 0.7 to 1.
- the DNA can be identified by washing the filter under 65 ° C conditions.
- Hybridization can be carried out according to the method described in Molecular 'Cloning Second Edition and the like.
- the hybridizable DNA specifically, in the above DNA, at least the base sequence represented by SEQ ID NO: 1 DNAs having a homology of 70% or more, preferably DNAs having a homology of 90% or more can be mentioned.
- the DNA encoding P-hydroxybenzoate-decaprenyl transferase is a DNA encoding a polypeptide selected from the following (a), (b) and (c): 9) production method;
- a polypeptide comprising an amino acid sequence having 60% or more homology with the amino acid sequence described in SEQ ID NO: 4 and having P-hydroxybenzoic acid-decaprenyl transferase activity.
- polypeptide having P-hydroxybenzoic acid-decaprenyltransferase activity at least 60% or more of the amino acid sequence of the polypeptide is required to maintain the activity of the polypeptide.
- DNA that can be hybridized in the above-mentioned DNA, specifically, DNA having at least 70% homology with the nucleotide sequence represented by SEQ ID NO: 3, preferably DNA having 90% or more homology is used. I can give it.
- the microorganism capable of producing ubiquinone-10 is a microorganism selected from the group consisting of a microorganism belonging to the genus Agrobacterium, a microorganism belonging to the genus Paracoccus and a microorganism belonging to the photosynthetic bacterium, as described in (1), (2) above. ), (5) or (9).
- microorganism belonging to the photosynthetic bacterium is a microorganism selected from the group consisting of microorganisms belonging to the genus Rhodobacter, Rhodomicrobium, Rhodopi la, Rhodosprillum and Rhodopseudomonas.
- a polypeptide comprising an amino acid sequence in which one or more amino acids are deleted, substituted or added in the amino acid sequence of the polypeptide of (a), and having decaprenyl diphosphate synthase activity
- polypeptide comprising an amino acid sequence having at least 60% homology with the amino acid sequence of SEQ ID NO: 4 and having P-hydroxybenzoate-decaprenyltransferase activity
- a DNA selected from the following (a), (b) and (c):
- microorganism capable of producing ubiquinone-10 is a microorganism selected from the group consisting of a microorganism belonging to the genus Agrobacterium, a microorganism belonging to the genus Paracoccus, and a microorganism belonging to the photosynthetic bacterium. body.
- microorganism belonging to the photosynthetic bacterium is a microorganism selected from the group consisting of microorganisms belonging to the genera Rhodobacter, Rhodomicrobium, Rhodopila, Rhodospirillum and Rhodops eudomonas. .
- the transformant according to any one of the above (27) to (31) is cultured in a medium, and ubiquinone-110 is produced and accumulated in the culture, and the ubiquinone-one is produced from the culture. 10.
- Ribosome A method for expressing the gene according to (33), wherein the NA gene is a liposomal RNA gene derived from a microorganism belonging to the genus Rhodobacter.
- nucleotide sequence of a DNA encoding a polypeptide derived from a microorganism capable of producing ubiquinone-10 wherein the nucleotide sequence has a nucleotide sequence in which one or more bases have been deleted, substituted or added, and A microorganism capable of producing ubiquinone-10, characterized by introducing a DNA encoding a polypeptide having an altered peptide activity into a microorganism capable of producing ubiquinone-10 by electroporation. How to make a mutant strain.
- the DNA encoding a polypeptide derived from a microorganism capable of producing ubiquinone-10 is a DNA having the nucleotide sequence of SEQ ID NO: 6,
- microorganism capable of producing ubiquinone-10 is a microorganism selected from the group consisting of a microorganism belonging to the genus Agrobacterium, a microorganism belonging to the genus Paracoccus, and a microorganism belonging to the photosynthetic bacterium. ).
- microorganism belonging to the photosynthetic bacterium is a microorganism selected from the group consisting of microorganisms belonging to the genera Rhodobacter, Rhodomicrobium, Rhodopila, Rhodospiri 1lum, and Rhodopseudomonas.
- Any microorganism capable of producing ubiquinone 10 can be used as a microorganism for constructing a microorganism having reduced or deficient crt E activity of the present invention, and examples thereof include microorganisms belonging to Agrobacterium jj and Paracoccus. Microorganisms belonging to the genus, microorganisms belonging to the photosynthetic bacteria and the like can be mentioned.
- microorganism belonging to the photosynthetic bacterium examples include microorganisms belonging to the genus Rhodobacter, Rhodomicrobiumpil, Rhodopilaspir, Rhodospiril lum, Rhod £ _seudom_oims and the like.
- Rhodobacter sphaeroides examples include Rhodobacter sphaeroides, Rhodobacter capsul tus And more specifically, R. sphaeroides ATCC17Q23 and sphaeroides FERM BP-4675.
- Methods for constructing microorganisms capable of producing ubiquinone 10 with reduced or deficient crt E activity include radiation such as ultraviolet light, X-rays, ⁇ -rays, sodium nitrite, nitrosogazine, and the like.
- radiation such as ultraviolet light, X-rays, ⁇ -rays, sodium nitrite, nitrosogazine, and the like.
- Mutant treatment using a chemical such as ethyl methylsulfonate according to a standard method, and selecting strains with reduced or deficient crt E activity from strains that have changed color of colonies when grown on an agar medium Can be given.
- the wild-type strain forms a red colony due to the accumulation of carotenoid, but in the mutant strain, the color of the colony changes to pink, yellow, or light purple depending on the location of the gene deletion. Therefore, a target mutant can be selected based on the color tone of the colony.
- a target strain can also be obtained by using a method for specifically introducing a mutation into a gene encoding crteE using genetic engineering techniques.
- Chromosomal DNA is extracted from a microorganism capable of producing ubiquinone-10 by a method described in, for example, Molecular and General Genetics, 213, 78-83 (1988) or Nucleic Acids Res., 18, 7267 (1990). be able to.
- the carotenoid biosynthesis-related enzyme gene class including crt E of R. sphaeroides Yuichi has already published the nucleotide sequence (J. Bacteriology, 177, 2064-2073 (1995)), and based on the nucleotide sequence information, Prepare primer DNA by a method using a DNA synthesizer.
- any DNA fragment containing crtE can be isolated by PCR using the chromosomal DNA derived from a microorganism having the ability to produce ubiquinone-10 obtained in (1) above as a type I PCR. .
- the sense primer used in the PCR reaction includes, for example, the sequence shown in SEQ ID NO: 7.
- Examples of the antisense primer include, for example, the sequence shown in SEQ ID NO: 8.
- DNA polymerase used in the PCR method examples include Takara Taq DNA polymerase (Takara Shuzo), TaKaRa LA-PCR TM Kit Ver.2 (Takara Shuzo) or Expand TM High-Fidelity PCR System (Beiringer).
- Takara Taq DNA polymerase Takara Shuzo
- TaKaRa LA-PCR TM Kit Ver.2 Takara Shuzo
- Expand TM High-Fidelity PCR System Beiringer
- Commercially available enzymes such as Mannheim can be used, and Takara PCR thermal cycler 480 (Takara Shuzo) or the like can be used for the PCR reaction.
- the reaction step consisting of 94 ° C for 30 seconds, 55 at 30 seconds to 1 minute, and ⁇ 2 ° C for 2 minutes is defined as one cycle. 20 seconds at 98 ° C when amplifying DNA fragments larger than 2 kb
- a reaction step consisting of 3 minutes at 68 ° C. may be defined as one cycle, and after 30 cycles, the reaction may be carried out at 72 ° C. for 7 minutes.
- the obtained amplified DNA fragments are separated by a technique such as agarose electrophoresis.
- the separated amplified DNA fragment is extracted and purified from agarose gel using, for example, a Mermaid kit (Bio 101 Inc. CA. USA) or the like.
- the purified DNA is ligated to an appropriate vector, for example, pCR2.1 (Invitrogen) using, for example, a TA cloning kit (Invitrogen).
- the amplified DNA fragment and an appropriate vector that can be amplified in Escherichia coli are cut with a restriction enzyme that recognizes the restriction enzyme site provided by the primer.
- the obtained cut DNA fragments are fractionated and recovered by agarose electrophoresis.
- the obtained two-cleaved DNA fragments are ligated according to a conventional method.
- a suitable host Escherichia coli for example, INVhi F '(Invitrogen) or DH5hi (Toyobo) is transformed.
- Transformants were applied to an agar medium containing a drug corresponding to the drug resistance gene of Vector-1, for example, LB agar medium containing 100 ⁇ g / m1 of ampicillin, and incubated at 37 ° C overnight. It can be selected by culturing.
- a plasmid containing the desired DNA is obtained, for example, by the method described in Molecular, Cloning, Second Edition and the like.
- DyeTerminator Cycle Sequencing FS Ready Reaction Kit Kino-Kinle Rema Japan
- 373A Sequencer Perkin Elma Japan
- the fact that the amplified sequence contains crtE indicates that the base sequence of the amplified It can be confirmed by comparing the knowledge sequence information.
- Reduction or deletion of the crtE activity of the photosynthetic bacterium can be achieved by causing deletion, substitution, or insertion mutation in all or a part of the crtE gene present on the chromosomal DNA. Further, the expression of the crtE gene may be suppressed.
- any commonly used mutagenesis method can be used as a method for causing deletion, substitution, or insertion mutation in all or a part of the crtE gene present on the chromosome.
- the deletion at the 5′-terminal and the 3′-terminal may be any deletion as long as the crtE activity of the recombinant strain is reduced or deleted.
- a deletion of a region necessary for transcription of the gene or a deletion of a region required for translation of the crte protein may be used.
- the circular DNA contains a marker gene such as a drug resistance gene to facilitate selection of recombinant strains, and is a target strain to be introduced in order to suppress the expression of the primary gene in non-recombinant strains.
- Circular DNA that does not have the ability of self-sustained amplification or becomes incapable of replication under certain conditions, such as a plasmid having a temperature-sensitive replication region, is preferred.
- the circular DNA may retain replication ability in a strain other than the target strain.
- (b) DNA containing a mutant gene in which all or part of the crt E gene has been deleted, substituted, or inserted is introduced into the target strain, and the DNA is deleted, substituted, or inserted at two points.
- the deletion, substitution, or insertion mutation of the mutated gene to be introduced is a mutation that reduces or lacks the crt E activity of a strain in which these mutations have been introduced into the gene on the chromosome. Any mutation may be used.
- the mutation on the chromosome is such that the crt E activity of the strain in which these mutations have been introduced is reduced or deleted, a region necessary for transcription of the gene or a region necessary for translation of the crt E protein.
- DNA into which a deletion, substitution, or insertion has been introduced can also be used.
- Methods for introducing DNA fragments into photosynthetic bacteria include conjugation transfer methods such as those described in Bio / Technology, 1, 784-791 (1983) and Gene, 118, 145-146 (1992). it can. In addition, an election port method can also be used.
- electroporation a commercially available device, for example, Gene Pulser II (manufactured by Bio-Rad) can be used.
- Selection of a strain in which crrtE activity has been reduced or deleted can be performed by simultaneously selecting a drug resistance expressed by a drug resistance gene integrated into a chromosome as a marker. Furthermore, it can be obtained by selecting a strain in which the color tone of the colony has changed due to a decrease or lack of carotenoid synthesis ability.
- the introduction of the mutation in the crt E gene indicates that the normal crt E gene isolated in (2) above was introduced into a strain in which the crt E activity was reduced or deleted, and the carotenoid biosynthesis ability was restored. It can be confirmed by whether or not to do.
- DNA encoding the decaprenyl diphosphate synthase of the present invention can be obtained from the microorganism described in [1], which has the ability to produce ubiquinone 10 by the following method.
- Two or more highly homologous portions of the amino acid sequence of a known polyprenyl diphosphate synthase are selected, and an oligodoxynucleotide containing a base sequence encoding the selected amino acid sequence is used as a sense primer, and The oligodoxynucleotide containing the complementary sequence of the base sequence encoding the selected amino acid sequence is used as an antisense primer, and the chromosomal DNA of a microorganism having the ability to generate ubiquinone 10 is used as a type I PCR. By doing so, DNA containing a partial fragment of the decaprenyl diphosphate synthase gene derived from the microorganism can be obtained.
- polyprenyl diphosphate synthase gene sequences include, for example, Bacillus subtil is, Bacillus stearothermophi lus Escherichia coli, Gluconobacter suboxydans, Haemophilus inf luenzae s Hericobacter pyloric Rhodobacter capsulatus Saccharomyces serevisiae, Schizosaccharomyces
- sequence of the polyprenyl diphosphate synthase gene derived from Synechocystis sp. PCC6803 can be mentioned. These sequences are available from public institutions databases, such as GenBank.
- the sense primer used in the PCR reaction includes, for example, the sequence shown in SEQ ID NO: 9.
- Examples of the antisense primer include, for example, the sequence shown in SEQ ID NO: 10. These oligodeoxynucleotides can be synthesized by a commonly used DNA synthesizer.
- Takara Taq DNA polymerase (Takara Shuzo Co., Ltd.) can be used as the DNA polymerase used in the PCR method.
- Takara PCR thermal cycler 480 (manufactured by Takara Shuzo) can be used.
- the PCR conditions were as follows: a reaction process consisting of 94 ° C for 45 seconds, 35 ° C for 45 seconds, 72 ° C for 1 minute was repeated 5 times, then 94 ° for 45 seconds, 45 ° ⁇ for 45 seconds, and 72 ° C for 45 seconds. Conditions under which the cycle of 1 minute at ° C is repeated 30 times can be given.
- the obtained plasmid DNA and the determination of the nucleotide sequence of the PCR amplified fragment contained in the obtained plasmid DNA can be performed according to the method described in [1].
- the amplified sequence contains the polybrenyl diphosphate synthase gene can be confirmed by comparing the base sequence of the amplified sequence with known sequence information.
- a DNA fragment containing the entire decaprenyl diphosphate synthase gene derived from a microorganism capable of producing ubiquinone-10 can be obtained from a microorganism capable of producing ubiquinone-10 using a DNA having a partial sequence of the gene. From the genomic library of origin, it can be isolated, for example, by the following method.
- Chromosomal DNA derived from a microorganism capable of producing ubiquinone-1 10 is extracted according to the method described in [1] (1), and then partially digested with an appropriate restriction enzyme such as Sau3AI, and the resulting digestion is obtained.
- the DNA fragment is fractionated by a conventional method such as sucrose density gradient ultracentrifugation.
- the DNA fragment of 30 to 40 kb in size obtained by the fractionation is ligated to a cosmid vector digested with an appropriate restriction enzyme such as Bam HI, for example, SuperCosI, and packaged into human phage.
- an appropriate restriction enzyme such as Bam HI, for example, SuperCosI
- a suitable host for example, Escherichia coli DH5 is transformed according to a conventional method (for example, the method described in Molecular 'Cloning, Second Edition) to obtain a transformant.
- the transformant is applied to an agar medium containing a drug corresponding to the drug resistance gene of the vector, for example, an LB agar medium containing 100 / g / m1 of ampicillin, and cultured overnight at 37 ° C. Can be selected.
- a cosmid having a DNA fragment containing the entire decaprenyl diphosphate synthase gene derived from a microorganism having an ability to produce ubiquinone-10 was prepared by using the following DNA as a probe. It can be confirmed by the Southern Hive Redistribution.
- the DNA to be used for the probe is prepared using a DNA and DIG oligonucleotide tiling kit (Beiringer Mannheim) containing the whole or a part of the base sequence determined in [2] (1). be able to. Using the probe and the DIG DNA detection kit (manufactured by Boehringer Mannheim), the desired DNA fragment can be detected.
- a DNA and DIG oligonucleotide tiling kit Beiringer Mannheim
- the cosmid extracted from the above transformant was designated as ⁇ type, and a P-type primer using a sense primer and an antisense primer designed based on the partial sequence of the previously determined decabrenyl diphosphate synthase gene was used.
- a cosmid having a DNA fragment containing the entire decaprenyl diphosphate synthase gene can be confirmed.
- the DNA fragment containing the decaprenyl diphosphate synthase gene can be fractionated and recovered by a method such as agarose gel electrophoresis after digesting the cosmid having the DNA fragment with a restriction enzyme.
- the size of the DNA fragment containing the decaprenyl diphosphate synthase gene can be determined by a conventional method, for example, the method described in Molecular Cloning Second Edition, after digesting the DNA containing the gene with an appropriate restriction enzyme, and then agarose gel. Min by electrophoresis After the fractionation, the DNA can be transferred and fixed on an appropriate membrane and subjected to Southern hybridization using the DIG-labeled DNA fragment as a probe.
- Purification of the DNA recovered from the agarose gel can be performed using, for example, Geneclean II kit (Bio 101 Inc. CA. USA).
- the purified DNA is ligated with, for example, a ligation kit Ver.2 (manufactured by Takara Shuzo) or the like, which is obtained by digesting an appropriate vector with a restriction enzyme to prepare a recombinant DNA.
- Ver.2 manufactured by Takara Shuzo
- E. coli such as ⁇ coli DH5 can be transformed to obtain a transformant having the recombinant DNA.
- Plasmid DNA of the transformant can be extracted according to a conventional method.
- the plasmid DNA is digested with an appropriate restriction enzyme according to a conventional method, for example, the method described in Molecular 'Cloning Second Edition, etc., and the obtained restriction enzyme fragment is fractionated and purified. After that, by ligating with an appropriate vector, a plasmid DNA having a restriction enzyme-digested DNA fragment of the plasmid DNA can be obtained.
- the whole or a part of the nucleotide sequence was sequenced using DyeTerminator Cycle Sequencin FS Ready Reaction Kit (manufactured by Perkin-Elma Japan) and 373A Sequencer (manufactured by Pakin-Elma Japan). Can be determined.
- the ORF and the amino acid sequence encoded by the ORF can be determined using commercially available base sequence analysis software, for example, Genetyx Mac (manufactured by Software Development).
- a DNA encoding the decaprenyl diphosphate synthase obtained by the above method for example, a polypeptide having the amino acid sequence of SEQ ID NO: 2
- a DNA encoding the peptide and having the nucleotide sequence set forth in SEQ ID NO: 1 can be mentioned.
- the DNA of the present invention is, in addition to the DNA obtained above, a DNA consisting of the nucleotide sequence of SEQ ID NO: 1, which is a DNA that hybridizes under stringent conditions, and decabrenyl diphosphate synthase DNAs encoding active polypeptides are also included.
- the DNA encoding the P-hydroxybenzoic acid mono-decaprenyltransferase of the present invention is more p-hydroxybenzoic acid than the microorganism described in [1], which has the ability to produce ubiquinone_10. It can be obtained by the following method using E. coli deficient in okinoprenyl transferase (ubiA) (hereinafter abbreviated as ubiA strain).
- ubiA E. coli deficient in okinoprenyl transferase
- Chromosomal DNA derived from a microorganism capable of producing ubiquinone-10 is extracted according to the method described in [1] (1), and then partially digested with an appropriate restriction enzyme such as Sau3AI, and the resulting digestion is obtained.
- the DNA fragment is fractionated by a conventional method such as sucrose density gradient ultracentrifugation.
- a recombinant DNA is prepared by ligating a DNA fragment having a size of 2 to 8 kb obtained by the fractionation with a plasmid vector digested with an appropriate restriction enzyme such as Bam HI, for example, pUC19. .
- a suitable host for example, Escherichia coli DH5 is transformed according to a conventional method (for example, the method described in Molecular Cloning Second Edition) to obtain a transformant.
- a chromosomal DNA library can be prepared.
- the transformant is prepared by adding a drug corresponding to the drug resistance gene of the vector.
- Agar medium for example, LB agar medium supplemented with 100 ⁇ g / m 1 of ampicillin, and cultured at 37 ° C. overnight.
- the plasmid possessed by the transformant is extracted according to a conventional method, and a ubiA-deficient strain is transformed using the plasmid.
- UbiA-deficient strains are available from the National Institute of Genetics, a public strain preservation agency.
- a ubiA-deficient strain can grow using glucose as a single carbon source, but cannot grow using succinic acid as a single carbon source. Therefore, if the plasmid extracted from the above-mentioned transformant contains DNA encoding p-hydroxybenzoic acid mono-decaprenyltransferase, the ubiA-deficient strain into which the plasmid has been introduced will contain only succinic acid. It can grow on an agar medium using one carbon source. Using this growth as an index, a plasmid containing DNA encoding P-hydroxybenzoic acid mono-decaprenyl transferase can be selected.
- the plasmid DNA of the transformant was extracted, and DyeTerniinator Cycle Sequencing FS Ready Reaction Kit (Pakkin Elmer
- the base sequence of the plasmid DNA is determined according to a conventional method using a 373A sequencer (manufactured by Perkin Elmer Japan) and a 373A sequencer.
- nucleotide sequence analysis software for example, Genetyx Mac (manufactured by Software Development).
- the DNA encoding P-hydroxybenzoic acid-polyprenyltransferase obtained by the above method may be, for example, an amino acid sequence represented by SEQ ID NO: 4.
- An example is DNA having a base sequence represented by SEQ ID NO: 3, which encodes a polypeptide having a noic acid sequence.
- the DNA of the present invention is, in addition to the DNA obtained above, a DNA comprising the nucleotide sequence of SEQ ID NO: 3, which hybridizes under stringent conditions, and p-hydroxybenzoic acid-polyprenyltrans. It also includes the DNA encoding Ferraz.
- the polypeptide of the present invention can be synthesized using the method described in Molecular 'Cloning 2nd Edition, Current-Protocols in' Molecular Biology, etc. It can be produced by expressing DNA encoding an enzyme or DNA encoding p-hydroxybenzoic acid-decaprenyltransferase in a host cell. If necessary, the polypeptide may be encoded based on the full-length DNA of the DNA encoding decaprenyl diphosphate synthase of the present invention or the DNA encoding p-hydroxybenzoate-decaprenyltransferase. Prepare an appropriate length of DNA fragment containing the desired fragment.
- a DNA is prepared by substituting the nucleotide sequence of the portion encoding the polypeptide of the present invention so that the nucleotide sequence becomes an optimal codon for host cell expression.
- the DNA is useful for efficient production of the polypeptide of the present invention.
- Recombinant DNA is prepared by inserting the DNA fragment or the full-length gene below the promoter of an appropriate expression vector.
- the recombinant DNA is introduced into a host cell compatible with the expression vector.
- any cell that can express the target gene such as bacteria, yeast, animal cells, insect cells, and plant cells, can be used.
- the expression vector may be an autonomously replicable or chromosome in the host cell.
- a promoter containing a promoter at a position where the DNA encoding the polypeptide of the present invention can be transcribed can be used.
- a recombinant DNA containing the DNA encoding the polypeptide of the present invention can be replicated autonomously in prokaryotes, and at the same time, a promoter and a ribosome can be used.
- the vector is composed of a binding sequence, the DNA of the present invention, and a transcription termination sequence. A gene that controls the promoter may be included.
- expression vectors include pBTrp2, pBTacl, and pBTac2 (all commercially available from Boehringer Mannheim), PKK233-2 (Pharmacia), pSE280 (Invitrogen), pGEMEX-1 (Promega) , QE-8 (manufactured by QIAGEN), pYPIO (JP-A-58-110600), pKYPZOO CAgric.Biol.Chem., 48, 669 (1984)], pLSAl CAgric.Biol.Chem., 53, 277 (1989) )), PGELl (Proc. Natl.Acad.Sci.
- any promoter may be used as long as it functions in the host cell.
- trp promoter Isseki one P trp
- lac promoter Isseki one P L promoter Isseki one
- P R promoter evening one such as T7 promoter, and the like promoter evening one derived from Escherichia coli or phage, etc. it can.
- the promoter evening one obtained by two series of P trp P trp x 2) , tac promoter Isseki one, lacT7 promoter, also be used the let I promoter Isseki artificially designed and modified promoters like one such it can.
- the promoter present in the ribosomal RNA gene In a microorganism capable of producing ubiquinone-10, it is preferable to use the promoter present in the ribosomal RNA gene.
- the promoter present in the ribosomal RNA gene include a promoter present in a ribosomal RNA gene derived from a microorganism belonging to the genus Rhodobacter. Specifically, a promoter containing a DNA having the nucleotide sequence of SEQ ID NO: 5 Can be raised.
- a plasmid in which the distance between the Shine-Dalgarno sequence, which is a ribosome binding sequence, and the initiation codon is adjusted to an appropriate distance (for example, 6 to 18 bases).
- the transcription termination sequence is not necessarily required for the expression of the DNA of the present invention, but it is preferable to arrange the transcription termination sequence immediately below the structural gene.
- Examples of host cells include microorganisms belonging to the genus Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas, etc., for example, Escherichia coli XL 1 -Blue, Escherichia coli XL2- Blue, Escherichia coli DH1, Escherichia coli DH5, Escherichia coli MC1000, Escherichia coli KY3276 S Escherichia coli W1485, Escherichia coli JM109, Escherichia coli HB10U Escherichia coli No.49, Escherichia coli W3110, Escherichia, Eschera TBI, Escherichia coli MP347.
- Escherichia coli XL 1 -Blue Escherichia coli XL2- Blue
- Escherichia coli DH1 Escherichia
- Serratia liquefaciens ⁇ Serratia marcescens Bacillus subtilis, Bacillus amyloliquefacines s Brevibacterium ammoniageneSs Brevibacterium immariophiluE ATCC14068, Brevibacterium saccharolyticum ATCC14066, Brevibacterium f lavum ATCC14067, Brevibacterium lactofermentiun ATCC13869, Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC14297, Corynebacterium acetoacidophilum ATCC13870, Microbacterium anunoniaphi lum ATCC15354, Pseudomonas put i da , Pseudomonas sp.
- Rhodopseudomonas blastica N Rhodopseudomonas marina ⁇ Rhodopseudomonas palustris.Rhodoscir i lium rubrunu Rhodospir ilium salexigens,
- Streptomyces griseochromogenes ⁇ Streptomyces griseus, Streptomyces lividanss Streptomyces olivogriseus, Streptomyces rameus, Streptomyces tanashiensiss Streptomyces viimceus Zymomonas mobilis and the like.
- any method for introducing DNA into the above host cells can be used.
- the protoplast method (JP-A-63-248394) or the method described in Gene, 17, 107 (1982) or Molecular & General Genetics, 168, 111 (1979).
- yeast When yeast is used as a host cell, as an expression vector, for example, YEP13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419), pHS19, pHS15 and the like.
- promoters for glycolytic genes such as hexose kinase, PH05 Promoter, PGK promoter , GAP promoter, A DH promoter overnight, gal 1 promoter overnight, gal 10 promoter overnight, heat shock polypeptide promoter, MF hi promoter, CUP 1 promoter overnight, etc. be able to.
- microorganisms belonging to the genera Saccharomyces, Schizosaccharomyces, Kluyveromyces ⁇ , Trichosporon, Schwann lomyces Pichi, Candiaa, etc. for example, Saccharomyces cerevisiae, Schizosaccharomyces pombe,
- Kluyveromyces lactis, Trichosporon pullulans, Schwanniomyces alluvius, Candida utilis and the like can be mentioned.
- any method can be used as long as it is a method for introducing DNA into yeast.
- elect opening method Qlethods EnzymoL, 194, 182 (1990) spheroplast method (Proc. Natl. Acad. Sci. USA, 75, 1929 (1978)], lithium acetate method (J. Bacteriology, 153, 163 (1983)), Proc. Natl. Acad. Sci. USA, 75, 1929 (1978). Methods can be given.
- an expression vector for example, cDNAI, pcDM8 (manufactured by Funakoshi), PAGE107 (JP-A-3-22979, Cytotechnology, 3, 133 (1990)), pAS3-3 (special Kaihei 2-227075), pCDM8 (Nature, 329, 840 (1987)), pcDNAI / Amp (manufactured by Invitrogen), pREP4 (manufactured by Invitrogen), pAGE103 (J. Biochem., 101, 1307 (1987)), pAGE210 Etc. can be given.
- CMV cytomegalovirus
- IE infectious ediate early Gene promoters
- SV40 early promoter SV40 early promoter
- retrovirus promoter SV40 early promoter
- meta-mouth thionine promoter heat shock promoter
- SR promoter etc.
- the enhancer of the IE gene of human CMV may be used together with the promoter.
- host cells examples include Namalwa cells, which are human cells, COS cells, which are monkey cells, CH0 cells, which are Chinese hamster cells, and HBT5637 (Japanese Patent Publication No. 63-299). .
- any method for introducing DNA into animal cells can be used.
- the electoporation method [Cytotechnology, 3, 133 (1990)] ]
- the calcium phosphate method Japanese Unexamined Patent Publication No. 2-227075
- the lipofection method [Pro Natl. Acad. Sci. USA, 84, 7413 (1987)]
- polypeptide can be expressed by the method described in Bio / Technology, 6, 47 (1988) and the like.
- the recombinant gene transfer vector and the baculovirus are co-introduced into insect cells to obtain the recombinant virus in the culture supernatant of the insect cells. Can be expressed.
- Examples of the gene transfer vector used in the method include, for example, pVU392, pVL1393, pBlueBacIII (all manufactured by Invitorogen) and the like.
- baculovirus for example, autographa cal ifornica nuclear polyhedrosis virus, which is a virus that infects night moth insects, can be used.
- insect cells Sf9 and Sf21 which are ovary cells of Spodoptera frugiperda (Baculovirus Expression Vectors, A Laboratory Manual, WH Freeman and Company, New York (1992)), and High 5 which is an ovarian cell of Trichoplusia (manufactured by Invitrogen) Etc. can be used.
- Methods for co-transferring the above-described recombinant gene into insect cells and the above baculovirus into insect cells for preparing a recombinant virus include, for example, calcium phosphate method (Japanese Patent Laid-Open No. 2-227075), and Lipofexion method. [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)].
- examples of the expression vector include Ti plasmid and tobacco mosaic virus vector.
- any promoter can be used as long as it can be expressed in plant cells.
- cauliflower mosaic virus (CaMV) 35S promoter, inineactin 1 promoter, etc. Can be.
- Examples of the host cell include plant cells of tobacco, potato, tomato, carrot, soybean, abrana, alfa alfa, rice, wheat, wheat, and the like.
- Any method for introducing the recombinant vector can be used so long as it is a method for introducing DNA into plant cells.
- Agrobacterium Japanese Patent Application Laid-Open No. 59-140885, 60-70080, W094 / 00977
- the electoral poration method JP-A-60-251887
- a method using a particle gun Gene gun
- Patent No. 2606856, Patent No. 2517813 Patent No. 2606856, Patent No. 2517813
- sugar-containing polypeptides When expressed in yeast, animal cells, insect cells, or plant cells, sugar-containing polypeptides can yield polypeptides with added sugar chains.
- the transformant of the present invention obtained as described above is cultured in a medium, and the polypeptide having the decaprenyl diphosphate synthesizing activity or the p-hydroxybenzoic acid-decaprenyl transferase activity of the present invention in the culture.
- the polypeptide of the present invention can be produced by producing and accumulating, and collecting from the culture.
- the method of culturing the above-obtained transformant in a medium can be performed according to a usual method used for culturing a host.
- the transformant of the present invention is a transformant obtained using a prokaryote such as Escherichia coli or a eukaryote such as yeast as a host
- the transformant can be used as a medium for culturing the transformant.
- Either a natural medium or a synthetic medium may be used as long as it contains a carbon source, a nitrogen source, inorganic salts, and the like, and can efficiently culture the transformant.
- the carbon source may be any as long as the transformant can be assimilated, such as glucose, fructose, sucrose, molasses containing them, carbohydrates such as starch or starch hydrolysate, and organic acids such as acetic acid and propionic acid. Alcohols such as ethanol, ethanol, and propanol can be used.
- Nitrogen sources include ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate and other ammonium salts of inorganic or organic acids, other nitrogen-containing compounds, and peptone, meat extract, yeast extract, corn steep liquor, Casein hydrolyzate, soybean meal, soybean meal hydrolyzate, various fermented cells and digests thereof can be used.
- potassium monophosphate potassium monophosphate, dipotassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate and the like can be used.
- the culture is performed under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the culturing temperature is preferably 15 to 40 ° C, and the culturing time is usually 16 hours to 7 days. It is preferable to maintain the pH during culturing between 3.0 and 9.0. pH adjustment should be Or using an organic acid, alkali solution, urea, calcium carbonate, ammonia, etc.
- an antibiotic such as ampicillin or tetracycline may be added to the medium during the culture.
- an Indian user may be added to the medium, if necessary.
- an Indian user may be added to the medium, if necessary.
- culturing a microorganism transformed with a recombinant vector using a promoter isopropyl-1 /?-D-thiogalactovyranoside, etc., and a microorganism transformed with a recombinant vector using a promoter.
- indoleacrylic acid or the like may be added to the medium.
- Culture is carried out usually p H 6 ⁇ 8, 3 0 ⁇ 4 0 ° C, 5% C 0 2 under the conditions such as the presence 1-7 days.
- antibiotics such as kanamycin and penicillin may be added to the medium during the culture.
- TNM-FH medium As a medium for culturing transformants obtained using insect cells as a host, commonly used TNM-FH medium (Pharmingen), Sf-900 II SFM medium (Life Technologies), ExCell400, ExCell405 ( In each case, JRH Biosciences, Grace's Insect Medium (Nature, 195, 788 (1962)) and the like can be used.
- the cultivation is usually performed under conditions of pH 6 to 7 and 25 to 30 ° C for 1 to 5 days. If necessary, an antibiotic such as genyumycin may be added to the medium during the culture.
- a transformant obtained using a plant cell as a host can be cultured as a cell or after being differentiated into a cell organ of a plant.
- a medium for culturing the transformant commonly used Murashige 'and' Skoog (MS) medium, white (White) medium, or a plant hormone such as auxin or cytokinin added to these mediums Media or the like can be used.
- Culture is usually performed at pH 5 to 9, 20 to 40 ° C for 3 to 60 days.
- antibiotics such as kanamycin and hygromycin may be added to the medium during the culture.
- a transformant derived from a microorganism, animal cell, or plant cell having a recombinant vector incorporating a DNA encoding the polypeptide of the present invention is cultured according to a conventional culture method.
- the polypeptide can be produced by producing and accumulating the polypeptide and collecting the polypeptide from the culture.
- the method for producing the polypeptide of the present invention includes a method of producing the polypeptide in a host cell, a method of secreting the polypeptide outside the host cell, and a method of producing the polypeptide on the host cell outer membrane.
- the method can be selected by changing the structure of the polypeptide.
- the polypeptide of the present invention When the polypeptide of the present invention is produced in the host cell or on the host cell outer membrane, the method of Paulson et al. [J. Biol. Chem., 264, 17619 (1989)], the method of Lowe et al. Natl. Acad. Sci. USA, 86, 8227 (1989), Genes Develop., 4, 1288 (1990)], or the method described in JP-A-5-336963, W094 / 23021, etc. Thereby, the polypeptide can be positively secreted out of the host cell. That is, the polypeptide of the present invention is expressed extracellularly by adding a signal peptide in front of the polypeptide containing the active site of the polypeptide of the present invention using a gene recombination technique. Can be actively secreted.
- the production amount can be increased using a gene amplification system using a dihydrofolate reductase gene or the like.
- the transgenic animal or plant cells are redifferentiated to create transgenic non-human animals or transgenic plants (transgenic plants) into which the gene has been introduced. Can be used to produce the polypeptide of the present invention.
- the transformant When the transformant is an animal or plant individual, the transformant is bred or cultivated according to a conventional method to produce and accumulate the polypeptide, and the polypeptide is collected from the animal or plant individual to obtain the polypeptide. Polypeptides can be produced.
- Examples of a method for producing the polypeptide of the present invention using an animal individual include, for example, known methods American Journal oi Clinical Nutrition, 63—, 639S (1996), American Journal of Clinical Nutrition, 63, 627S (1996). Bio / Technology, 9, 830 (1991)], and producing the polypeptide of the present invention in an animal constructed by introducing a gene.
- a transgenic non-human animal into which a DNA encoding the polypeptide of the present invention has been introduced is bred, and the polypeptide is produced and accumulated in the animal.
- the polypeptide By collecting the polypeptide, the polypeptide can be produced.
- the place of production and accumulation in the animal include milk of the animal (JP-A-63-309192), eggs, and the like.
- any promoter can be used as long as it can be expressed in animals.
- mammary gland cell-specific promoters such as Hikain Promote, Casein Promote, 5 Lactoglobulin Promote, and whey acid protein promoter are preferably used.
- a transgenic plant into which DNA encoding the polypeptide of the present invention has been introduced can be prepared by a known method [tissue culture, 20 (1994) Tissue culture, 21 (1995), Trends in Biotechnology, 15, 45 (1997)], producing and accumulating the polypeptide in the plant, and collecting the polypeptide from the plant.
- tissue culture 20 (1994) Tissue culture, 21 (1995), Trends in Biotechnology, 15, 45 (1997)
- producing and accumulating the polypeptide in the plant and collecting the polypeptide from the plant.
- a method for producing the polypeptide can be mentioned.
- the cells when expressed in a lysed state in cells, the cells are recovered by centrifugation after completion of the culture, suspended in an aqueous buffer, and then subjected to an ultrasonic crusher, French press, Menton. The cells are disrupted using a Gaulin homogenizer, Dynomill, etc. to obtain a cell-free extract.
- a normal enzyme isolation and purification method that is, a solvent extraction method, a salting-out method using ammonium sulfate, a desalting method, and a precipitation using an organic solvent Method
- anion-exchange mouth chromatography using resins such as getylaminoethyl (DEAE) -Sepharose, DIAION HPA-75 (Mitsubishi Kasei), and resins such as S-Sepharose FF (Pharmacia) Chromatography using a resin such as butyl sepharose, phenylsepharose, etc., molecular sieve, gel filtration, affinity chromatography, chromatography
- a refined sample can be obtained by using a technique such as a caching method or an electrophoresis method such as isoelectric focusing alone or in combination.
- the cells When the polypeptide is expressed by forming an insoluble form in the cells, the cells are similarly collected, crushed, and centrifuged to collect the insoluble form of the polypeptide as a precipitate fraction. I do.
- the recovered insoluble form of the polypeptide is solubilized with a protein denaturant.
- the polypeptide is returned to a normal three-dimensional structure by diluting or dialyzing the solubilized solution and reducing the concentration of the protein denaturing agent in the solubilized solution. After this operation, a purified preparation of the polypeptide can be obtained by the same isolation and purification method as described above.
- the polypeptide of the present invention or a derivative such as a polypeptide having a sugar chain added to the polypeptide is secreted extracellularly
- the polypeptide or the derivative of the polypeptide is added to the culture supernatant.
- polypeptide having the amino acid sequence of SEQ ID NO: 2 may be used for a polypeptide having decaprenyl diphosphate synthesis activity.
- polypeptide having a protease activity include a polypeptide having an amino acid sequence described in SEQ ID NO: 4.
- polypeptide of the present invention comprises, in addition to the polypeptide obtained above, an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence of the polypeptide, Also included are polypeptides having decaprenyl diphosphate synthesizing activity or polypeptides having 4-hydroxybenzoic acid-decaprenyl transphenylase activity.
- the polypeptide of the present invention can also be produced by a chemical synthesis method such as the Fmoc method (fluorenylmethyloxycarbonyl method) and the tBoc method (t-butyloxycarbonyl method). Can be. Also, Advanced ChemTech, Perkin 'Norema, Pharmacia, Protein Technology Instrument, Synthecell-Vega Chemical synthesis can also be performed using a peptide synthesizer such as PerSeptive, Shimadzu Corporation.
- Microorganisms used for the production of ubiquinone-10 include those with reduced or deficient crt E activity, enhanced decaprenyl diphosphate synthase activity, and those with P-hydroxybenzoate-decaprenyltransferase activity. Microorganisms capable of producing ubiquinone 10 having one or more properties selected from the group consisting of enhanced properties are preferred.
- Examples of a microorganism capable of producing ubiquinone 10 having a property of reducing or losing crtE activity include the microorganism obtained in [1].
- a microorganism having an enhanced property of decaprenyl diphosphate synthase activity or an enhanced property of P-hydroxybenzoate-decaprenyltransferase activity may be used as a ubiquinone-10 in accordance with the mutagenesis method described in [1].
- DNA encoding decaprenyl diphosphate synthase or DNA encoding P-hydroxybenzoate-decaprenyltransferase obtained by the methods described in [2] and [3] is used to produce ubiquinone-10. It can be obtained by introducing it into a microorganism having the ability to do so according to the method described in [4].
- Microorganisms having the ability to produce ubiquinone-10 having at least one property selected from the group consisting of the following properties can be obtained.
- Ubiquinone-10 has reduced or absent crt E activity, enhanced decaprenil diphosphate synthase activity, and P-hydroxybenzoic acid-de Selected from the group consisting of enhanced properties of cabrenyltransferase activity
- a microorganism having at least one property and capable of producing ubiquinone-10 is cultured in a medium, ubiquinone-10 is produced and accumulated in the culture, and the ubiquinone-10 is collected from the culture. can do.
- the culture can be performed according to the culture method described in [4]. During the culture, if necessary, aromatic compounds such as shikimic acid, chorismate, p-hydroxybenzoic acid, which are precursors of biosynthesis of ubiquinone-10, and isoprenide compounds such as IPP and FPP are added to the medium. You may.
- Ubiquinone_10 can be collected from the culture solution using a collection method used in ordinary organic synthetic chemistry, such as extraction with an organic solvent, crystallization, thin-layer chromatography, high-performance liquid chromatography, and the like.
- the collected ubiquinone-10 can be confirmed and quantified by 13 C-NMR spectrum, 'H-NMR spectrum, mass spectrum, high performance liquid chromatography (HPLC), colorimetric method and the like.
- the promoter present in the ribosomal RNA gene described in the method for producing a polypeptide of [4] above is useful not only for the method for producing a polypeptide of [4] but also for general polypeptides. It is also useful in manufacturing methods.
- the polypeptide By inserting a DNA encoding a polypeptide intended for expression downstream of a DNA consisting of a base sequence of a promoter present in the ribosome RNA gene, the polypeptide can be efficiently converted.
- the coding DNA can be expressed, and the polypeptide can be produced.
- the ribosomal RNA gene includes a ribosomal RNA gene derived from a microorganism belonging to the genus Rhodobacter.
- a specific example of the promoter present in the ribosomal RNA gene is a DNA having the nucleotide sequence of SEQ ID NO: 5. Examples of the present invention will be described below, but the present invention is not limited to these examples. The genetic recombination experiments described in the following Examples were performed using the method described in Molecular Cloning, Second Edition (hereinafter, referred to as ordinary method) unless otherwise specified.
- the chromosomal DNA of R. sphaeroides strain KY4113 (FERM BP-4675) was transferred to an LB medium [1% Bacto Tryptone (Difco), 0.5% Bacto Yeast Extract (Difco), 0.5% NaCl] 5 After overnight culture using Oml, the cells were collected. After the cells were once freeze-thawed, they were suspended in 10 ml of a buffer [0.5 mmol / l Tris HC 1, 2 Ommo 1/1 EDTA (pH 8.0)] containing 0.5 mg / ml lysozyme. And incubated at 37 ° C for 3 hours.
- the chromosome DNA was subjected to PCR amplification using a primer set having the nucleotide sequence shown in SEQ ID NO: 7 or 8 and synthesized as described above.
- the PCR was performed using TaKaRa LA-Taq under conditions of 30 cycles, with the reaction process consisting of 98 at 20 seconds and 68 ° C for 5 minutes as one cycle.
- the target DNA fragment of about 2.5 kb amplified by PCR is blunt-treated, After the phosphorylation treatment, the plasmid was inserted into the SmaI site of the plasmid vector pUC19 to prepare a recombinant plasmid.
- Escherichia coli DH5 strain (manufactured by Toyobo Co., Ltd.) was transformed using the recombinant plasmid, and the transformant was applied to a 1 ⁇ 8 agar medium containing 100 ⁇ / 1111 of ampicillin to obtain a transformed strain.
- Plasmid was extracted from the transformant, and the nucleotide sequence of DNA inserted into the SmaI site of the plasmid was determined.
- the plasmid was named pUCRTE-1.
- pUCRTE-1 is double-digested with Ba1I and StuI, and after confirming complete digestion by agarose gel electrophoresis, a DNA fragment of about 4.6 kb is excised and QIAEX II (manufactured by Qiagen). ) was used to purify the DNA fragment. The purified DNA fragment was subjected to a blunt treatment and a dephosphorylation treatment.
- a plasmid in which a kanamycin resistance gene was inserted into the obtained DNA was prepared as follows.
- the kanamycin resistance gene derived from Tn5 and the g1nB promoter overnight region from .sphaeroides Microbiology, 140, 2143-2151 (1994)] were isolated and ligated by PCR, followed by blunting and phosphorylation. After treatment, it was ligated to the previously prepared 4.6 kb DNA fragment to prepare a recombinant plasmid.
- Plasmid was extracted from the transformant, and it was confirmed that the kanamycin resistance gene was inserted into the crtE deletion site.
- the plasmid was named pUACRTE-1.
- the pUACRTE-1 obtained in (1) above was introduced into the sphaeroidesKY4113 strain by the following method.
- the KY4113 strain was inoculated into an LB liquid medium and cultured until the logarithmic growth phase. After the culture, the cells were collected by centrifugation. The obtained cells were washed twice with an aqueous solution containing 10% glycerol and 1 mmol / 1 HEPES to remove medium components as much as possible.
- the washed cells and 10 ⁇ g of pUACRTE-1 were placed in a 0.1 cm wide cuvette for electroporation (manufactured by Bio-Rad), and were subjected to 400 ⁇ using a gene pulser (manufactured by Bio-Rad). Elect opening was performed under the conditions of 25 ° F, 12.5 kv / cm, and pUACRTE_l was introduced into the cells.
- the cells were added to S0C medium (20 g of Bacto Tryptone (manufactured by Difco), 5 g of Bacto Yeast Extract (manufactured by Difco), 2 ml of 5mo1 / 1 NaC, and 1.25 ml of 2mo1 / KCI. After autoclaving the solution adjusted to 990 ml with water, the medium was cultured at 30 ° C. for 3 hours using a medium prepared by adding 10 ml of a 2 mol / 1 glucose solution to the solution. The resulting culture was spread on an LB agar medium containing 10 ⁇ G / m 1 kanamycin, and cultured for 3 days at 30 a C.
- S0C medium 20 g of Bacto Tryptone (manufactured by Difco), 5 g of Bacto Yeast Extract (manufactured by Difco), 2 ml of 5mo1 / 1 NaC, and 1.25 ml of 2mo1 / K
- chromosomal DNA was extracted and analyzed.
- the seven strains that had lost carotenoid productivity were forced into the crtE gene on the chromosome. It was found that the namycin resistance gene was inserted.
- pUACRTE-1 introduced by electoporation crosses the chromosomal homologous region at two points upstream and downstream of the kanamycin resistance gene and is inserted.
- the crt E gene is deleted and the crt E gene is deleted. It was thought that the enzyme activity (GGPP synthesizing activity) coded by the enzyme was lost and carotenoids could not be produced.
- the chromosomal DNA of these strains did not contain the ampicillin resistance gene in pUACRTE-1, and the DNA derived from the vector was not integrated into the chromosomal DNA.
- the obtained crtE-deficient strain was designated as KY4113AC rtE-1 to 7 strains.
- a normal crtE gene was introduced into the KY4113AC rtE-1 to 7 strains, and the carotenoid-producing ability was restored, confirming that the strain was a crtE-deficient strain. That is, a recombinant plasmid was prepared by inserting a normal crtE gene into the broad host range vector PEG400 [J, Bacteriology, 172, 2392 (1990)], and the plasmid was introduced into the strain, and a carotenoid dye was obtained. Was confirmed to be produced.
- Example 1 5 ml of the seed medium [glucose 2%, peptone 1%, yeast extract 1%, NaC 10.5% (pH 7.2, adjusted with NaOH)] was used for the KY4113AC rt E-1 to 7 strains obtained in Example 1.
- One platinum loop was inoculated into the test tube and cultured at 30 ° C for 24 hours.
- the obtained extract was centrifuged to collect a 2-butanol layer.
- HPLC high performance liquid chromatography
- KY4113Ac ⁇ tE-7 7 shares 24.7 159.5 6.5
- the production amount of ubiquinone-10 was significantly higher in the ⁇ 4113 ⁇ crt E-l ⁇ 7 strain compared to the control KY4113 strain. That is, it has been found for the first time that the productivity of ubiquinone-10 can be improved by deficient in crt E activity of sphaeroides.
- the method does not require a special vector or host necessary for the conjugation method, and any vector that cannot be replicated autonomously by photosynthetic bacteria, for example, PUC19, can be used.
- DNA can also be used.
- the present inventors considered that by enhancing the ubiquinone biosynthesis system, it was possible to efficiently produce ubiquinone 110, and attempted to obtain a gene relating to the ubiquinone biosynthesis system.
- DPPS decaprenyl diphosphate synthase gene
- the nucleotide sequence corresponding to the extracted amino acid sequence is designed in consideration of the frequency of codon usage of ⁇ sphaeroides, and a DNA fragment having the nucleotide sequence of SEQ ID NO: 9 is used as a sense primer, and a SEQ ID NO: A DNA fragment having the base sequence described in 10 was synthesized using a DNA synthesizer.
- the PCR was performed under the condition that a reaction process consisting of 94 at 40 seconds, 60 ° C. for 40 seconds, and 72 at 45 seconds was defined as one cycle, and 35 cycles were performed.
- An amplified fragment of about 400 bp was obtained by PCR.
- the nucleotide sequence of the DNA fragment was determined, and it was confirmed that the DNA fragment had a high homology with a known polyprenyl diphosphate synthase.
- the DNA fragment was purified and labeled with DIG using a DIG DNA Labeling Kit (Boehringer Mannheim).
- strain KY4113 In order to obtain the full length of the decaprenyl diphosphate synthase gene of R. sphaeroides strain KY4113, a genomic library of strain KY4113 was prepared by the following method.
- the KY4113 strain was cultured overnight in LB medium, and chromosomal DNA was extracted. After partial digestion with the restriction enzyme Sau3AI, a 4-6 kb DNA fragment was purified by sucrose density gradient ultracentrifugation. The DNA fragment and the vector pUC19 digested with BamHI were ligated using a Ligation Pack (manufactured by Tsubon Gene) to prepare a recombinant plasmid.
- a Ligation Pack manufactured by Tsubon Gene
- the transformant was subjected to screening by Koguchi knee hybridization to obtain a total of five colonies that hybridized with the DIG-labeled DNA fragment. . Plasmids were extracted from strains derived from the colonies by a conventional method and subjected to restriction enzyme digestion to compare the sizes of the inserted DNA fragments.
- the size of the inserted DNA fragments of the above five strains was the same, and when the DNA fragments were sequenced, they had a common sequence.
- the sequence contained an ORF encoding 333 amino acids highly homologous to polyprenyl diphosphate synthase genes of other species.
- the nucleotide sequence is shown in SEQ ID NO: 1, and the amino acid sequence is shown in SEQ ID NO: 2.
- Example 3 An about 4 kb DNA fragment containing the DPPS gene cloned in Example 3 was ligated to a broad host range vector PEG400 to prepare a recombinant plasmid.
- This plasmid was named pEGDPPS-II.
- pEGDPPS-1 and pEG400 as a control were introduced into the KY4113 strain and the KY4113 mucrE-1 strain obtained in Example 1 by the elect-mouth poration method.
- the electroporation was performed using Gene Pulser (manufactured by Bio-Rad) under the conditions of 400 ⁇ , 25 ° F., and 12.5 kv / cm.
- the plasmid-introduced cells were cultured in SOC medium for 3 hours at 30 ° C, and then applied to LB agar medium containing 100 ⁇ g / ml of spectinomycin. The cells were cultured at ° C for 3 days. The grown transformant was cultured, and plasmid was extracted from the obtained cells, and it was confirmed that each strain retained the introduced plasmid.
- the obtained transformants were named KY4113 / pEGDPPS-KY4113 / pEG400, KY4113Ac r t E-1 / pEGDPPS-1 and KY4113AC r t E-l / pEG400, respectively.
- Each of the obtained transformants was inoculated with a platinum loop into a test tube containing 5 ml of a seed medium supplemented with 100 ⁇ g / ml of spectinomycin and cultured at 30 ° C. for 24 hours.
- Ubiquinone-110 was extracted from the culture solution after the completion of the culture according to the method described in Example 2, and quantitatively analyzed by HPLC to determine the production amount of ubiquinone-10.
- ubiquinone-10 containing (10) the ubiquinone-10 precursor was significantly higher in the KY4113 / pEGDPPS-1 strain than in the control KY4113 / pEG400 strain. Furthermore, by using the KY4113AcrtE-1 strain as the host, higher productivity of ubiquinone-110 was demonstrated.
- decaprenyl 2-phosphate synthesis is rate-limiting in ubiquinone-110 biosynthesis, and decaprenyl 2
- the FPP pool which is a substrate for acid synthase, was found to increase.
- promoters of microorganisms capable of producing ubiquinone-10 there is information on promoters that are highly expressed under anaerobic photosynthetic culture conditions, but little information on aerobic heterotrophic culture conditions.
- RNA gene sequence has already been published, and three types of rrnA, rrnB, and rrnC are known (Nucleic Acids Res., 18, 7267-7277 (1990)).
- the upstream sequence of the RNA gene was subjected to PCR cloning by the following method.
- a DNA fragment having the nucleotide sequence of SEQ ID NO: 11 is used as a sense primer to obtain a DNA fragment having the nucleotide sequence of SEQ ID NO: 12, Designed as an antisense primer.
- a restriction enzyme XbaI site was added to the sense primer
- a restriction enzyme KpnI site was added to the antisense primer
- a ribosome binding site was designed as the antisense primer.
- the PCR was performed under the conditions that a reaction process consisting of 94 ° C. for 40 seconds, 60 ° C. for 40 seconds, and 72 ° C. for 45 seconds was defined as one cycle, and 30 cycles of reaction were performed.
- An amplified fragment of about 200 bp was obtained by PCR.
- the nucleotide sequence of the DNA fragment was determined, and it was confirmed that the DNA fragment was the target DNA fragment.
- the DNA fragment was ligated to the upstream of the kanamycin resistance gene to create a recombinant plasmid which was inserted into the broad host range vector PEG400.
- the recombinant plasmid was introduced into the R. sphaeroides KY4113 strain by the electroporation method, and the resulting strain was applied to an LB agar medium containing 100 ⁇ g / l of spectinomycin, and then incubated at 30 ° C for 3 days. After culturing, a transformant was obtained.
- the transformants were evaluated on LB agar medium containing force namycin.
- kanamycin did not grow at 10 ⁇ g / l, but the recombinant plasmid having rnC upstream DNA was transfected.
- the obtained transformant was able to grow even at 100 g / l of kanamycin, confirming that the obtained upstream sequence of rRNA had strong promoter overnight activity.
- expression of the DPPS gene was attempted by the following method. Based on the DPPS gene sequence information derived from ⁇ sphaeroides confirmed in Example 3, the ORF portion was PCR amplified.
- primers examples include a sense primer, a DNA obtained by adding a restriction enzyme KpnI site (5 ′ ccggtacc 3 ′) to the 5 ′ end of DNA having a base sequence of 1 to 24 of SEQ ID NO: 1, an antisense primer.
- a sense primer a DNA obtained by adding a restriction enzyme KpnI site (5 ′ ccggtacc 3 ′) to the 5 ′ end of DNA having a base sequence of 1 to 24 of SEQ ID NO: 1, an antisense primer.
- KpnI site 5 ′ ccggtacc 3 ′
- an antisense primer As an additional sequence (5 'cc 3')
- Ec0RI site 5 'gaattc 3'
- the termination codon (5 'tea 3') is replaced with bases 979 to 990 of SEQ ID NO: 1.
- the DNA added to the 5 and 5 ends of the sequence complementary sequence was used.
- a PCR reaction was carried out according to the method of Example 3.
- the DNA in the promoter region that had been PCR amplified above was digested with XbaI and KpnI and purified.
- the above two DNA fragments were ligated to the XbaI, EcoRI double digest of the broad host range vector PEG400 to obtain a recombinant plasmid, and the recombinant plasmid was ligated.
- the nucleotide sequence of the inserted DNA was determined, and it was confirmed that the recombinant plasmid had the DPPS gene ligated immediately below the target rrnC upstream sequence.
- the recombinant plasmid was named pEGrrnC-DPPS-1.
- the recombinant plasmid pEGrrnC-DPPSl constructed in Example 5 and pEG400, pEGDPPS-1, and pEGglnB-DPPSl as controls were electorated by EK4113 strain. Introduced by the method.
- the cells into which the plasmid had been introduced were cultured in an SOC medium at 30 ° C for 3 hours.
- the obtained culture solution was applied to an LB agar medium containing spectinomycin at 10 Og / ml, and cultured at 30 ° C for 3 days.
- Plasmid was extracted from the cells obtained by culturing the grown transformant, and it was confirmed that each of the introduced plasmids was retained.
- the transformants obtained by the above method were named KY4113 / pEGrrnC-DPPS1, KY4113 / pEG400 KY4113 / pEGDPPS-1, and KY4113 / pEGglnB-DPPS1, respectively.
- Each of the obtained transformants was inoculated in a test tube containing 5 ml of a seed medium supplemented with 100 ⁇ g / ml of spectinomycin and cultured at 30 ° C. for 24 hours at 30 ° C.
- 0.5 ml of the obtained culture solution was added to a test tube containing 5 ml of ubiquinone_10 production medium supplemented with 100 ⁇ g / ml of spectinomycin, followed by shaking culture at 30 ° C. for 5 days. .
- Ubiquinone-10 was extracted from the broth after completion of the culture according to the method described in Example 2, and quantitatively analyzed by HPLC to calculate the production amount of ubiquinone-10.
- ubiquinone-10 Since the production of ubiquinone-10 was highest in KY4113 / pEGrrnC-DPPS-1, ubiquinone was enhanced by enhancing the expression of decaprenyl diphosphate synthase. It has been found that productivity can be improved very efficiently. Also, the rRNA-derived promoter was found to be much stronger than the previously known glnB promoter overnight and useful for the production of ubiquinone-110.
- Example 7 Cloning of p-hydroxybenzoate-decaprenyltransferase gene from R. sphaeroides
- Chromosome DNA of R. sphaeroides FERM BP-4675 was obtained by the method of Example 1 (1), and 200 g of the obtained 200 g of chromosomal DNA was partially digested with Sau3AI.
- the obtained partially digested DNA fragment was fractionated by sucrose density gradient ultracentrifugation, and a DNA fragment having a size of 2 to 8 kb was ligated to a plasmid vector pUC19 digested with BamHI.
- Cells obtained by transforming Escherichia coli DH5 strain using the ligation product according to a conventional method are applied to 1 ⁇ B agar medium supplemented with ampicillin 100 // 1111, and cultured at 37 ° C overnight.
- a genomic library consisting of about 50,000 transformants was prepared.
- a plasmid contained in the transformant constituting the genomic library 1 was extracted by a conventional method, and the plasmid was used to delete p-hydroxybenzoic acid prenyl prenyltransferase (ubi A).
- ubi A p-hydroxybenzoic acid prenyl prenyltransferase
- a ubi A-deficient strain was transformed.
- the resulting transformant, M 9 minimal agar medium succinate as a single carbon source (N a 2 HP 0 4 6 g / ls KH 2 P 0 4 3 g / l, NaC l 5 g / l, NH 4 C l
- Plasmid was extracted from one transformant grown on M9 minimal agar medium using succinic acid as the sole carbon source according to a conventional method, and re-introduced into the ubiA-deficient strain. It was confirmed that the ub i A-deficient strain was given the ability to grow on a single carbon source of succinate.
- the nucleotide sequence of the DNA fragment inserted into the plasmid was determined using a 373A sequencer (Perkin Elmer Japan).
- the determined nucleotide sequence was analyzed with Genetyx Mac (manufactured by SoftTube Development Corp.), and a polypeptide having high homology to the amino acid sequence of a known p-hydroxybenzoate-polyprenyltransferase was encoded. It was confirmed that there was an ORF.
- Example 8 Production of ubiquinone-10 by a transformant having a high expression type plasmid, p-hydroxybenzoate-decaprenyltransferase gene
- a primer for PCR was designed. At that time, a primer having a restriction enzyme KpnI as a sense primer and a restriction enzyme EcoRI recognition sequence added to its 5 'end was used as an antisense primer.
- Both ends of the obtained amplified DNA fragment were digested with KpnI and EcoRI, and the DNA fragment was purified by a conventional method.
- the DNA fragment obtained above and the two DNA fragments of the promoter DNA derived from rrnC having XbaI and KpnI recognition sequences at both ends obtained in Example 5 were combined with a broad host range. It was ligated to XbaI and EcoRI double digest of PEG400 to obtain recombinant plasmid.
- the plasmid possessed by the transformant was extracted by a conventional method, and the inserted DNA fragment of the plasmid was extracted. was determined.
- plasmid was constructed in which DNA encoding p-hydroxybenzoic acid-decaprenyltransferase was ligated downstream of the glnB promoter derived from the KY4113 strain overnight.
- pEGglnB-ubiAl DNA encoding p-hydroxybenzoic acid-decaprenyltransferase was ligated downstream of the glnB promoter derived from the KY4113 strain overnight.
- the constructed plasmids pEGrraC-ubiAl and pEGglnB-ubiAl and PEG400 as a control were introduced into the KY4113 strain by an electroporation method.
- the cells into which the plasmid had been introduced were cultured in an SOC medium at 30 ° C. for 3 hours.
- the obtained culture solution was applied to an LB agar medium containing 100 ⁇ g / ml of spectinomycin, and cultured at 30 ° C. for 3 hours.
- Plasmid was extracted from the cells obtained by culturing the grown transformant, and it was confirmed that each of the introduced plasmids was retained.
- the transformant obtained in this manner was designated KY4113 / pEGrrnC-ubiAl,
- KY4113 / pEGglnB-ubiAK This was named KY4113 / pEG400, respectively.
- Each of the obtained strains was inoculated in a test tube containing 5 ml of a seed medium supplemented with 100 / g / ml of spectinomycin and cultured at 30 ° (24 hours).
- Ubiquinone-110 was extracted from the broth after completion of the culture according to the method described in Example 2, and quantitatively analyzed by HP LC to calculate the production amount of Ubiquinone-110.
- the production amount of ubiquinone-10 was significantly higher in the KY4113 / pEGglnB-ubiAl and KY4113 / pEGrrnC-ubiAl strains as compared to the control KY4113 / pEG400 strain.
- the KY4113 / pEGrrnC-ubiAl strain showed the highest ubiquinone-10 productivity.
- a method for producing ubiquinone-110 useful as an antioxidant substance a method for producing ubiquinone useful as an antioxidant functional substance, a microorganism and a microorganism useful for the production, a method for gene expression in the microorganism, and A method for breeding the microorganism can be provided. Sequence listing free text
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2385132A CA2385132C (en) | 1999-10-14 | 2000-10-13 | Process for producing ubiquinone-10 |
EP00966472A EP1227155B1 (en) | 1999-10-14 | 2000-10-13 | Process for producing ubiquinone-10 |
DE60038565T DE60038565T2 (de) | 1999-10-14 | 2000-10-13 | Verfahren zur herstellung von ubiquinon-10 |
JP2001530489A JP4668495B2 (ja) | 1999-10-14 | 2000-10-13 | ユビキノン−10の製造法 |
US10/110,393 US7422878B1 (en) | 1999-10-14 | 2000-10-13 | Process for microbial production of ubiquinone-10 using Rhodobacter |
AU76860/00A AU7686000A (en) | 1999-10-14 | 2000-10-13 | Process for producing ubiquinone-10 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29195999 | 1999-10-14 | ||
JP11/291959 | 1999-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001027286A1 true WO2001027286A1 (fr) | 2001-04-19 |
Family
ID=17775687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/007121 WO2001027286A1 (fr) | 1999-10-14 | 2000-10-13 | Procédé de production d'ubiquinone-10 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7422878B1 (ja) |
EP (1) | EP1227155B1 (ja) |
JP (1) | JP4668495B2 (ja) |
AT (1) | ATE391787T1 (ja) |
AU (1) | AU7686000A (ja) |
CA (3) | CA2718652C (ja) |
DE (1) | DE60038565T2 (ja) |
WO (1) | WO2001027286A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1383864A2 (en) * | 2000-09-29 | 2004-01-28 | Cargill Incorporated | Isoprenoid production |
JP2006517794A (ja) * | 2003-02-19 | 2006-08-03 | デーエスエム アイピー アセッツ ベー. ヴェー. | CoQ10の微生物による生成 |
JP2006212019A (ja) * | 2004-04-30 | 2006-08-17 | National Institute Of Agrobiological Sciences | 植物を用いたユビキノン−10の製造方法 |
JP2007151496A (ja) * | 2005-12-07 | 2007-06-21 | Toyota Motor Corp | 遺伝子組換えによるユビキノン−10の製造方法 |
WO2008063020A1 (en) * | 2006-11-24 | 2008-05-29 | Sk Energy Co., Ltd. | Rhodobacter sphaeroides sk2h2 strain having high content of coenzyme q10 and the method of producing coenzyme q10 using the same |
EP1931765A2 (de) | 2005-09-28 | 2008-06-18 | Cellca GmbH | Verbessertes zellkulturmedium |
JP2014500031A (ja) * | 2010-12-21 | 2014-01-09 | サンボ インターナショナル エスタブリッシュメント | 光合成微生物中のCoQ10およびCoQH2の含有量を増加させる方法 |
JP2014166191A (ja) * | 2001-12-27 | 2014-09-11 | Kaneka Corp | 補酵素q10の製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1641931B1 (en) * | 2003-07-08 | 2008-11-19 | DSM IP Assets B.V. | Improved production of coenzyme q-10 |
WO2007120423A2 (en) * | 2006-03-20 | 2007-10-25 | Microbia Precision Engineering | Production of quinone derived compounds in oleaginous yeast and fungi |
CN108795968A (zh) * | 2017-05-03 | 2018-11-13 | 华东理工大学 | 一种类球红细菌高产菌株的遗传转化方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08107789A (ja) * | 1994-10-13 | 1996-04-30 | Alpha- Shokuhin Kk | ユビキノン−10の製造方法 |
US6103488A (en) * | 1997-08-27 | 2000-08-15 | Alpha Foods Co., Ltd. | Method of forming ubiquinone-10 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06189775A (ja) * | 1992-10-06 | 1994-07-12 | Alpha- Shokuhin Kk | ユビキノン生合成鍵酵素ubiA遺伝子 |
JPH1057072A (ja) * | 1996-08-22 | 1998-03-03 | Alpha- Shokuhin Kk | ユビキノン−10の生成方法 |
US6225097B1 (en) | 1997-09-17 | 2001-05-01 | Toyota Jidosha Kabushiki Kaisha | Decaprenyl diphosphate synthetase gene |
JPH11178590A (ja) | 1997-09-17 | 1999-07-06 | Toyota Motor Corp | デカプレニル二リン酸合成酵素遺伝子 |
AU9635901A (en) * | 2000-09-29 | 2002-04-08 | Cargill Inc | Isoprenoid production |
-
2000
- 2000-10-13 AU AU76860/00A patent/AU7686000A/en not_active Abandoned
- 2000-10-13 WO PCT/JP2000/007121 patent/WO2001027286A1/ja active IP Right Grant
- 2000-10-13 CA CA2718652A patent/CA2718652C/en not_active Expired - Fee Related
- 2000-10-13 CA CA2385132A patent/CA2385132C/en not_active Expired - Fee Related
- 2000-10-13 CA CA2722337A patent/CA2722337A1/en not_active Abandoned
- 2000-10-13 EP EP00966472A patent/EP1227155B1/en not_active Expired - Lifetime
- 2000-10-13 JP JP2001530489A patent/JP4668495B2/ja not_active Expired - Fee Related
- 2000-10-13 DE DE60038565T patent/DE60038565T2/de not_active Expired - Lifetime
- 2000-10-13 AT AT00966472T patent/ATE391787T1/de not_active IP Right Cessation
- 2000-10-13 US US10/110,393 patent/US7422878B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08107789A (ja) * | 1994-10-13 | 1996-04-30 | Alpha- Shokuhin Kk | ユビキノン−10の製造方法 |
US6103488A (en) * | 1997-08-27 | 2000-08-15 | Alpha Foods Co., Ltd. | Method of forming ubiquinone-10 |
Non-Patent Citations (3)
Title |
---|
DATABASE EMBL/GENBANK/DDBJ [online] XP002936042, Database accession no. AJ010302 * |
HAJIME YOSHIDA ET AL.: "Production of ubiquinone-10 using bacteria", JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 44, no. 1, February 1998 (1998-02-01), pages 19 - 26, XP002936043 * |
SYLVIA C. DRYDEN ET AL.: "Identification of cis-Acting Regulatory Regious Upstream of the rRNA Operons of Rhodobacter sphaeroides", JOURNAL OF BACTERIOLOGY, vol. 175, no. 20, October 1993 (1993-10-01), pages 6392 - 6402, XP002936041 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1383864A4 (en) * | 2000-09-29 | 2005-01-26 | Cargill Inc | ISOPRENOIDPRODUKTION |
AU2001296359B2 (en) * | 2000-09-29 | 2006-04-27 | Cargill Incorporated | Isoprenoid production |
EP1383864A2 (en) * | 2000-09-29 | 2004-01-28 | Cargill Incorporated | Isoprenoid production |
US9315839B2 (en) | 2001-12-27 | 2016-04-19 | Kaneka Corporation | Processes for producing coenzyme Q10 |
US9926580B2 (en) | 2001-12-27 | 2018-03-27 | Kaneka Corporation | Process for producing coenzyme Q10 |
JP2014166191A (ja) * | 2001-12-27 | 2014-09-11 | Kaneka Corp | 補酵素q10の製造方法 |
JP2006517794A (ja) * | 2003-02-19 | 2006-08-03 | デーエスエム アイピー アセッツ ベー. ヴェー. | CoQ10の微生物による生成 |
JP2006212019A (ja) * | 2004-04-30 | 2006-08-17 | National Institute Of Agrobiological Sciences | 植物を用いたユビキノン−10の製造方法 |
EP1931765A2 (de) | 2005-09-28 | 2008-06-18 | Cellca GmbH | Verbessertes zellkulturmedium |
JP2007151496A (ja) * | 2005-12-07 | 2007-06-21 | Toyota Motor Corp | 遺伝子組換えによるユビキノン−10の製造方法 |
JP4702025B2 (ja) * | 2005-12-07 | 2011-06-15 | トヨタ自動車株式会社 | 遺伝子組換えによるユビキノン−10の製造方法 |
WO2008063020A1 (en) * | 2006-11-24 | 2008-05-29 | Sk Energy Co., Ltd. | Rhodobacter sphaeroides sk2h2 strain having high content of coenzyme q10 and the method of producing coenzyme q10 using the same |
JP2014500031A (ja) * | 2010-12-21 | 2014-01-09 | サンボ インターナショナル エスタブリッシュメント | 光合成微生物中のCoQ10およびCoQH2の含有量を増加させる方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE391787T1 (de) | 2008-04-15 |
EP1227155A1 (en) | 2002-07-31 |
CA2385132C (en) | 2010-12-14 |
US7422878B1 (en) | 2008-09-09 |
CA2718652C (en) | 2014-07-29 |
DE60038565T2 (de) | 2009-06-10 |
EP1227155A4 (en) | 2004-07-28 |
DE60038565D1 (de) | 2008-05-21 |
EP1227155B1 (en) | 2008-04-09 |
JP4668495B2 (ja) | 2011-04-13 |
CA2722337A1 (en) | 2001-04-19 |
CA2718652A1 (en) | 2001-04-19 |
AU7686000A (en) | 2001-04-23 |
CA2385132A1 (en) | 2001-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1072683B1 (en) | Process for producing isoprenoid compounds by using microorganisms | |
EP1778843B1 (en) | Production of isoprenoids | |
US7999151B2 (en) | Method of producing astaxanthin or metabolic product thereof by using carotenoid ketolase and carotenoid hydroxylase genes | |
US7422878B1 (en) | Process for microbial production of ubiquinone-10 using Rhodobacter | |
US20090226986A1 (en) | Production of Coenzyme Q-10 | |
KR100768016B1 (ko) | 신규 트랜스알도라아제 유전자 | |
WO2022133254A1 (en) | Amycolatopsis strains for vanillin production with suppressed vanillic acid formation | |
JP4412779B2 (ja) | 放線菌由来のメバロン酸経路に関与する酵素の遺伝子 | |
JP4401471B2 (ja) | 微生物によるイソプレノイド化合物の製造方法 | |
WO2001057223A1 (fr) | Enzyme dans le processus non mevalonate et gene la codant | |
CN1982450A (zh) | 利用微生物生产类异戊二烯化合物的方法和检测具有抗菌或除草活性的化合物的方法 | |
JP2003033188A (ja) | エバーメクチン誘導体の製造法 | |
JP2000300257A (ja) | 抗菌または除草活性化合物の探索方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 530489 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2385132 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000966472 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000966472 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000966472 Country of ref document: EP |